WASHINGTON (MedPage Today) -- The FDA is reviewing safety data from an ongoing trial of the asthma drug omalizumab (Xolair) after interim results showed an excess of cardiovascular and cerebrovascular events among patients taking the drug.
Cardiovascular Events in Omalizumab Trial Prompt FDA ScrutinyCourtesy MedPage Today Allergy & Immunology Thu, 07/16/2009 - 16:49
WASHINGTON (MedPage Today) -- The FDA is reviewing safety data from an ongoing trial of the asthma drug omalizumab (Xolair) after interim results showed an excess of cardiovascular and cerebrovascular events among patients taking the drug. More related itemsACAAI: Asthma Drug Effective in Skin Condition...
AAAAI: Drug Speeds Up Milk Allergy Tx (CME/CE, with...
Asthma Drug Cuts Seasonal Flares for Inner-City Kids...
|
Post new comment